DOCSLIB.ORG

Drug Metabolism & Pharmacokinetics in Drug Discovery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Metabolism & Pharmacokinetics in Drug Discovery Drug Metabolism & Pharmacokinetics in Drug Discovery: A Primer for Bioanalytical Chemists, Part I Chandrani Gunaratna In the face of advancing technology in combinatorial synthesis and high Bioanalytical Systems Inc. 2701 Kent Avenue throughput screening, the drug discovery process continues to evolve. West Lafayette, IN Preclinical drug metabolism and pharmacokinetics studies play a key role 47906-1382 in lead identification and optimization. This fast-paced development [email protected] process has imposed an enormous burden on the analytical chemist to design faster and more sensitive assay techniques to aid the drug discovery and development. This article, Part I of a two-part series introduces the analytical chemist to the fundamentals of drug metabolism. Part II of this series will discuss the pharmacokinetics aspects and how drug metabolism data can be used to predict pharmacokinetic parameters. Technological innovation and the ciency in the optimization of desired liphophilicity and stability are deter- pressures of competition have pharmacological activity in humans mined by measuring the octanol- caused enormous changes in the while decreasing the reliance on ani- water partition coefficient and pKa. drug discovery process. Progress in mal studies has become a challenge. These measurements are useful in molecular biology and the Human New chemical entities (NCEs) enter predicting the protein binding, tissue Genome Project has contributed to the drug discovery pipeline through distribution and absorption in the the remarkable advances made in combinatorial synthesis and rational gastrointestinal tract (1). identification of new therapeutic tar- drug design where information The selected leads are further gets. The drug discovery process is about the target of action is used to screened using in vitro tests during rapidly evolving due to the techno- design the lead compound. HTS lead optimization. The goal of lead logical developments in target iden- helps the identification of the leads optimization is to select compounds tification along with automation of that provide the required effect at with required biological activity in combinatorial synthesis and high high concentrations. In the secon- humans. Relevant pharmacokinetic throughput screening (HTS). In light dary screening stage physicochemi- parameters such as tissue penetra- of these advances, improving effi- cal properties such as solubility, tion, stability, intestinal absorption, F1 metabolism, and elimination are ob- CHEMICAL COMBINATORIAL Drug development tained using in vitro systems. These process (IND: in vitro systems include mi- Investigational New Lead Identification Drug, NDA: New Drug DISCOVERY crosomes, hepatocytes or tissue Application) slices for metabolite identification HIGH THROUGHPUT SCREENING Lead Optimiz and evaluation of metabolic path- PHYSIOCHEMICAL PROPERTIES inical ways and rates, and caco-2 cell lines l -c IN VITRO SCREENS re for evaluating transcellular absorp- P udies ation t IN VIVO SCREENS tion. Cytotoxicity data can be ob- tion S File IND c tained by using organ-specific cell PHASE I lines. Knowledge of the toxic poten- PHASE II nical ug Intera li r C D tial of these early leads and their PHASE III File NDA possible metabolites is essential for successful drug discovery. Most REGISTRATION drug candidates fail at this stage and only a few will be judged sufficiently MARKET safe and efficacious to proceed fur- ther into development. Both in vitro 17 Current Separations 19:1 (2000) F2 Oral Intestines drug as schematically shown in F3 is Absorption of a drug after known as ADME studies. administration. Topical Skin Drug Metabolism DRUG IV BLOOD Interest in drug or xenobiotic (for- IM, SC, IP Membranes eign compounds) metabolism can be dated back to the early 19th century. Inhalation Lung Metabolism then was known as a “detoxication” mechanism in the F3 body. In late 1930s, with the discov- ery of the synthetic azo-dye Pron- Schematic representation sm Metabolites of drug’s path from blood. Drug at metaboli tosil’s metabolism to antibacterial absorption Drug in Absorption agent sulfanilamide in the body, Site Blood elimination studying metabolism has become an Urine important priority. This year BAS distribution and the International Society for the Other Other Study of Xenobiotics (ISSX) pro- Distribution Tissues Excretory Fluids Fluids duced a historical calendar celebrat- ing many of the original and in vivo studies are then carried drug metabolism and pharmacoki- contributions to our knowledge of out on the active candidate com- netics aspects in drug discovery. Part the metabolism of organic com- pounds. The objective in these pre- 1 of the article covers the basics of pounds (3). clinical studies is not only to identify drug metabolism. In Part II we will Metabolism is the mechanism of the most active leads with the most discuss the kinetics of drug metabo- elimination of foreign and undesir- appropriate safety profiles but also, lism and the relationship of kinetic able compounds from the body and to select the closest animal species to data to the pharmacokinetics of a the control of levels of desirable the human for toxicity studies (2). drug. compounds such as vitamins in the Understanding of pharmacokinetic body. Since information on the me- and metabolism characteristics of Path of a drug tabolism of a drug plays a significant the selected compounds is needed in role in selection and further charac- designing appropriate human clini- After administration by any route, a terization of the drug, an in-depth cal trials. Various stages of drug dis- drug will reach the blood stream as look at the mechanism of drug meta- covery are illustrated in F1. schematically shown in F2.This bolism is worth the effort. Meeting the objectives of drug process is known as absorption. The The major site of metabolism in metabolism research, whether it be drug in the blood distributes rapidly the body is the liver. Metabolism in in vitro or in vivo, requires the proc- between the plasma and blood cells liver occurs in two stages: Phase I essing of a very large number of and also between plasma proteins. pathways in liver microsomes where samples for the determination of Most drugs readily cross the capillar- the drug is functionalized and Phase drug candidates and metabolites. ies and reach the extracellular fluid II pathways in liver cells where the There is likewise a lot of structural of every organ. Lipid soluble drugs parent or the metabolite from Phase chemistry to be done to identify me- cross the cell membranes and distrib- I gets conjugated. Liver microsomes tabolites. It is important for analyti- ute into the intracellular fluid of vari- are in the endoplasmic reticulum of cal chemists to understand that the ous tissues. This process of liver cells or hepatocytes. Phase I vast majority of compounds (actu- transferring a drug from blood to reactions in microsomes are cata- ally > 99.99%) will never become various tissues is called distribution. lyzed by a group of enzymes known drugs. Thus the bioanalytical work A drug is eliminated either di- as the cytochrome P450 system that must be fast. Often elegance must be rectly through an excretory route plays a significant role in drug meta- traded for speed early in the process. such as urine, bile etc. which is bolism. The common chemical reac- Later on, for example in clinical tri- known as elimination; or indirectly tions involved in Phase I are aromatic als, the number of samples for a par- through enzymatic or biochemical hydroxylation, aliphatic hydroxyla- ticular compound will increase transformation by the liver. The lat- tion, oxidative N-dealkylation, oxi- exponentially and carefully vali- ter path of elimination is called me- dative O-dealkylation, S-oxidation, dated methods are both required and tabolism. The study of this whole reduction and hydrolysis. Most often justified. process of absorption, distribution, this simple functionalization could This article is intended to en- metabolism and elimination of a be sufficient to make a drug more lighten bioanalytical chemists on soluble, facilitating elimination www.currentseparations.com 18 T1 toxic and carcinogenic action of Enzyme Substrates Known Cytochrome xenobiotics. P450 substrates. CYP1A2 Amitriptyline, Betaxolol, Caffeine, Clomipramine, Clozapine, There are about 30 human cyto- Chlorpromazine, Fluvoxamine, Haloperidol, Imipramine, chrome P450 enzymes, out of which Olanzapine, Ondansetron, Propranolol, Tacrine, Theophylline, only six, CYP1A2, CYP2C9, Verapamil, (R)-Warfarin CYP2C19, CYP2D6, CYP2E1 and CYP2A6 Coumarin, Betadiene, Nicotine CYP3A4 are the major metabolizing enzymes. CYP3A is the most abun- CYP2C9 Amitriptyline, Diclofenac, Demadex, Fluoxetine, Ibuprofen, Losartan, Naproxen, Phenytoin, Piroxicam, Tolbutamide, dant and most clinically important (S)-Warfarin isozyme in humans. It metabolizes nearly 50% of the clinically available CYP2C19 Amitriptyline, Citalopram, Clomipramine, Diazepam, Imipramine, Omeprazole drugs. T1 shows the major CYPs involved in the metabolism of some CYP2D6 Amitriptyline, Betaxolol, Clomipramine, Codeine, Clozapine, known drugs. From the table it can Desipramine, Fluoxetine, Haloperidol, Imipramine, Methadone, Metoclopramide, Metoprolol, Nortriptyline, Olanzapine, be seen that some drugs are metabo- Ondansetron, Paroxetine, Propranolol, Risperidone, Sertraline, lized by more than one isozyme. This Timolol, Venlafaxine multiple-substrate metabolism is the CYP2E1 Acetaminophen,
Load more

Recommended publications
  • 1: Clinical Pharmacokinetics 1
    1: CLINICAL PHARMACOKINETICS 1 General overview: clinical pharmacokinetics, 2 Pharmacokinetics, 4 Drug clearance (CL), 6 Volume of distribution (Vd), 8 The half-life (t½), 10 Oral availability (F), 12 Protein binding (PB), 14 pH and pharmacokinetics, 16 1 Clinical pharmacokinetics General overview General overview: clinical pharmacokinetics 1 The ultimate aim of drug therapy is to achieve effi cacy without toxicity. This involves achieving a plasma concentration (Cp) within the ‘therapeutic window’, i.e. above the min- imal effective concentration (MEC), but below the minimal toxic concentration (MTC). Clinical pharmacokinetics is about all the factors that determine variability in the Cp and its time-course. The various factors are dealt with in subsequent chapters. Ideal therapeutics: effi cacy without toxicity Minimum Toxic Concentration (MTC) Ideal dosing Minimum Effective Concentration (MEC) Drug concentration Time The graph shows a continuous IV infusion at steady state, where the dose-rate is exactly appropriate for the patient’s clearance (CL). Inappropriate dosing Dosing too high in relation to the patient’s CL – toxicity likely Minimum Toxic Concentration (MTC) Minimum Effective Concentration (MEC) Dosing too low in relation to the Drug concentration patient’s CL – drug may be ineffective Time Some reasons for variation in CL Low CL High CL Normal variation Normal variation Renal impairment Increased renal blood fl ow Genetic poor metabolism Genetic hypermetabolism Liver impairment Enzyme induction Enzyme inhibition Old age/neonate 2 General overview Clinical Pharmacokinetics Pharmacokinetic factors determining ideal therapeutics If immediate effect is needed, a loading dose (LD) must be given to achieve a desired 1 concentration. The LD is determined by the volume of distribution (Vd).
    [Show full text]
  • Pharmacokinetics, Biodistribution, and Pharmacodynamics of Drug Delivery Systems
    JPET Fast Forward. Published on March 5, 2019 as DOI: 10.1124/jpet.119.257113 This article has not been copyedited and formatted. The final version may differ from this version. JPET # 257113 Title: Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems Authors: Patrick M. Glassman, Vladimir R. Muzykantov Affiliation: Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania Address: 3400 Civic Center Boulevard, Bldg 421, Philadelphia, Pennsylvania 19104-5158, United States Downloaded from jpet.aspetjournals.org at ASPET Journals on September 24, 2021 1 JPET Fast Forward. Published on March 5, 2019 as DOI: 10.1124/jpet.119.257113 This article has not been copyedited and formatted. The final version may differ from this version. JPET # 257113 Running Title: PK/PD Properties of Drug Delivery Systems Corresponding Authors: Vladimir R. Muzykantov ([email protected], (215) 898-9823) and Patrick M. Glassman ([email protected]) # of Text Pages: 22 # of Tables: 2 # of Figures: 4 Word Count – Abstract: 144 Word Count – Introduction: 350 Word Count – Discussion: N/A Downloaded from Non-Standard Abbreviations: Absorption, Distribution, Metabolism, and Elimination (ADME) Biodistribution (BD) Drug Delivery Systems (DDSs) Enhanced Permeability & Retention (EPR) jpet.aspetjournals.org Gastrointestinal (GI) Intravenously (IV) Neonatal Fc Receptor (FcRn) Monoclonal Antibody (mAb) Reticuloendothelial System (RES) at ASPET Journals on September 24, 2021 Pharmacodynamics (PD) Pharmacokinetics (PK) Physiologically-Based Pharmacokinetic (PBPK) Subcutaneously (SC) Target-Mediated Drug Disposition (TMDD) Recommended Section: Drug Discovery and Translational Medicine 2 JPET Fast Forward. Published on March 5, 2019 as DOI: 10.1124/jpet.119.257113 This article has not been copyedited and formatted.
    [Show full text]
  • Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
    Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
    [Show full text]
  • Importance of ADME and Bioanalysis in the Drug Discovery
    alenc uiv e & eq B io io B a f v o a i l l a Journal of a b Vuppala et al., J Bioequiv Availab 2013, 5:4 n r i l i u t y o DOI: 10.4172/jbb.10000e31 J ISSN: 0975-0851 Bioequivalence & Bioavailability EditorialResearch Article OpenOpen Access Access Importance of ADME and Bioanalysis in the Drug Discovery Pradeep K Vuppala1*, Dileep R Janagam2 and Pavan Balabathula2 1Preclinical Pharmacokinetics Shared Resource, St. Jude Children’s Research Hospital, Memphis, TN, USA 2University of Tennessee Health Sciences Center, Memphis, TN, USA Editorial Bioanalytical support plays a vital role during the lead optimization stages. The major goal of the bioanalysis is to assess the over-all The hunt for new drugs can be divided into two stages: discovery ADME characteristics of the new chemical entities (NCE’s). Arrays and development. Drug discovery includes generating a hypothesis of of bioanalytical methods are required to completely describe the the target receptor for a particular disorder and screening the in vitro pharmacokinetic behavior in laboratory animals as well as in humans and/or in vivo biological activities of the new drug candidates. Drug [7]. Bioanalytical tools can play a significant role for the progress development involves the assessment of efficacy and toxicity of the new in drug discovery and development. Physiologic fluids such as blood, drug candidates. serum, plasma, urine and tissues are analyzed to determine the absorption and disposition of a drug candidate administered to a test To aid in a discovery program, accurate data on pharmacokinetics animal [8].
    [Show full text]
  • Measuring Ligand Efficacy at the Mu- Opioid Receptor Using A
    RESEARCH ARTICLE Measuring ligand efficacy at the mu- opioid receptor using a conformational biosensor Kathryn E Livingston1,2, Jacob P Mahoney1,2, Aashish Manglik3, Roger K Sunahara4, John R Traynor1,2* 1Department of Pharmacology, University of Michigan Medical School, Ann Arbor, United States; 2Edward F Domino Research Center, University of Michigan, Ann Arbor, United States; 3Department of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, United States; 4Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, United States Abstract The intrinsic efficacy of orthosteric ligands acting at G-protein-coupled receptors (GPCRs) reflects their ability to stabilize active receptor states (R*) and is a major determinant of their physiological effects. Here, we present a direct way to quantify the efficacy of ligands by measuring the binding of a R*-specific biosensor to purified receptor employing interferometry. As an example, we use the mu-opioid receptor (m-OR), a prototypic class A GPCR, and its active state sensor, nanobody-39 (Nb39). We demonstrate that ligands vary in their ability to recruit Nb39 to m- OR and describe methadone, loperamide, and PZM21 as ligands that support unique R* conformation(s) of m-OR. We further show that positive allosteric modulators of m-OR promote formation of R* in addition to enhancing promotion by orthosteric agonists. Finally, we demonstrate that the technique can be utilized with heterotrimeric G protein. The method is cell- free, signal transduction-independent and is generally applicable to GPCRs. DOI: https://doi.org/10.7554/eLife.32499.001 *For correspondence: [email protected] Competing interests: The authors declare that no Introduction competing interests exist.
    [Show full text]
  • Second Generation Inhibitors of BCR- ABL for the Treatment of Imatinib- Resistant Chronic Myeloid Leukaemia
    REVIEWS Second generation inhibitors of BCR- ABL for the treatment of imatinib- resistant chronic myeloid leukaemia Ellen Weisberg*, Paul W. Manley‡, Sandra W. Cowan-Jacob§, Andreas Hochhaus|| and James D. Griffin¶ Abstract | Imatinib, a small-molecule ABL kinase inhibitor, is a highly effective therapy for early-phase chronic myeloid leukaemia (CML), which has constitutively active ABL kinase activity owing to the expression of the BCR-ABL fusion protein. However, there is a high relapse rate among advanced- and blast-crisis-phase patients owing to the development of mutations in the ABL kinase domain that cause drug resistance. Several second-generation ABL kinase inhibitors have been or are being developed for the treatment of imatinib- resistant CML. Here, we describe the mechanism of action of imatinib in CML, the structural basis of imatinib resistance, and the potential of second-generation BCR-ABL inhibitors to circumvent resistance. The BCR-ABL oncogene, which is the product of the design of new drugs to circumvent resistance, and Philadelphia chromosome (Ph) 22q, encodes a chimeric several new agents have been developed specifically BCR-ABL protein that has constitutively activated ABL for this purpose. These compounds have been well tyrosine kinase activity; it is the underlying cause of characterized for efficacy against the mutant enzymes chronic myeloid leukaemia (CML)1–3. Whereas the 210 in preclinical studies, and impressive therapeutic activ- kDa BCR-ABL protein is expressed in patients with ity has now been reported for two second generation CML, a 190 kDa BCR-ABL protein, resulting from an drugs in phase I and II clinical trials in patients with *Dana Farber Cancer alternative breakpoint in the BCR gene, is expressed in imatinib-resistant CML.
    [Show full text]
  • Medicinal Chemistry
    Medicinal Chemistry Dr. Shuaib Alahmad Medicinal and Pharmaceutical Chemistry References: 1- Wilson and Gisvold’s Text book of Organic Medicinal & Pharmaceutical Chemistry, Twelfthe Edition, 2011 2- Gareth Thomas’’ Medicinal Chemistry; An Introduction,2nd Edition. 2007. 3- Dr.Iyad Allous lectures 2 Introduction Medicinal Chemistry: is the discovery, the development, the identification and the interpretation of the mode of action of biologically active compounds that can be used as drugs for the prevention, treatment or cure of human and animal diseases. Medicinal chemistry includes the study of already existing drugs, of their biological properties and their structure-activity relationships. During the early stages of medicinal chemistry development, scientists were primarily concerned with the isolation of medicinal agents found in plants. Today, scientists in this field are also equally concerned with the creation of new synthetic compounds as drugs. Medicinal chemistry is devoted to the discovery and development of new agents for treating diseases. 3 Introduction The primary objective of Medicinal Chemistry is the design and discovery of new compounds that are suitable for use as drugs. This process involves a team of workers from a wide range of disciplines such as chemistry, biology, biochemistry, pharmacology, mathematics, medicine and computing, amongst others 4 Introduction Medicinal chemistry covers the following stages: I.The first stage is lead discovery in which new active substances or drugs are identified and prepared
    [Show full text]
  • Targeting CD133 Reverses Drug-Resistance Via the AKT/NF-κB/MDR1 Pathway in Colorectal Cancer
    www.nature.com/bjc ARTICLE Translational Therapeutics Targeting CD133 reverses drug-resistance via the AKT/NF- κB/MDR1 pathway in colorectal cancer Zeting Yuan1,2, Xin Liang3, Yueping Zhan4, Ziyuan Wang5, Jian Xu4, Yanyan Qiu1, Jie Wang6, Yijun Cao6, Van-Minh Le7, Hai-Trieu Ly7, Jianhua Xu1, Wei Li6, Peihao Yin1,2,6 and Ke Xu1,2,4 BACKGROUND: Recent studies have shown that multidrug resistance may be induced by the high stemness of cancer cells. Following prolonged chemotherapy, MDR protein 1 (MDR1) and CD133 increase in CRC, but the relationship between them is unclear. METHODS: The relationship between MDR and CSC properties in CRC was determined via CCK-8 assay, apoptosis assay, DOX uptake and retention, immunohistochemistry, immunofluorescence and flow cytometry. The correlations between their expression levels were evaluated using Spearman’s rank statistical test and the Mann-Whitney test. Furthermore, the effect of CD133 on the repression of the AKT/NF-κB/MDR1 signalling pathway was investigated in vitro and in vivo. RESULTS: We found that CD133 increased with the emergence of drug-resistance phenotypes, and the high expression of MDR1/P- gp was consistently accompanied by positive expression of CD133 as demonstrated by the analysis of patient samples. Up- or downregulation of CD133 could regulate MDR via AKT/NF-κB/MDR1 signalling in CRC. A rescue experiment showed that the AKT/ NF-κB signalling pathway is the main mechanism by which CD133 regulates MDR1/P-gp expression in CRC. CONCLUSIONS: Taken together, our results suggest that targeting CD133 reverses drug resistance via the AKT/NF-κB/MDR1 pathway and that this pathway might serve as a potential therapeutic target to reverse MDR in CRC.
    [Show full text]
  • Antimalarial Drug Efficacy and Drug Resistance: 2000–2010 WHO Library Cataloguing-In-Publication Data
    GLOBAL REPORT ON ANTIMALARIAL DRUG EFFICACY AND DRUG RESISTANCE: 2000–2010 WHO Library Cataloguing-in-Publication Data Global report on antimalarial drug efficacy and drug resistance: 2000-2010. 1.Malaria - prevention and control. 2.Malaria - drug therapy. 3.Antimalarials - therapeutic use. 4.Epidemiologic surveillance - methods. 5.Drug resistance. 6.Drug monitoring. 7.Treatment outcome. 8.Thailand. 8.Cambodia. I.World Health Organization. ISBN 978 92 4 150047 0 (NLM classification: QV 256) © World Health Organization 2010 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Method of Rough Estimation of Median Lethal Dose (Ld50)
    b Meta olis g m & ru D T o f x o i Journal of Drug Metabolism and l c a o n l o r Saganuwan, J Drug Metab Toxicol 2015, 6:3 g u y o J Toxicology DOI: 10.4172/2157-7609.1000180 ISSN: 2157-7609 Research Article Open Access Arithmetic-Geometric-Harmonic (AGH) Method of Rough Estimation of Median Lethal Dose (Ld50) Using Up – and – Down Procedure *Saganuwan Alhaji Saganuwan Department of Veterinary Physiology, Pharmacology and Biochemistry, College Of Veterinary Medicine, University Of Agriculture, P.M.B. 2373, Makurdi, Benue State, Nigeria *Corresponding author: Saganuwan Alhaji Saganuwan, Department of Veterinary Physiology, Pharmacology and Biochemistry, College Of Veterinary Medicine, University Of Agriculture, P.M.B. 2373, Makurdi, Benue State, Nigeria, Tel: +2348027444269; E-mail: [email protected] Received date: April 6,2015; Accepted date: April 29,2015; Published date: May 6,2015 Copyright: © 2015 Saganuwan SA . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Earlier methods adopted for the estimation of median lethal dose (LD50) used many animals (40 – 100). But for the up – and – down procedure, 5 – 15 animals can be used, the number I still consider high. So this paper seeks to adopt arithmetic, geometric and harmonic (AGH) mean for rough estimation of median lethal dose (LD50) using up – and – down procedure by using 2 – 6 animals that may likely give 1 – 3 reversals. The administrated doses should be summed up and the mean, standard deviation (STD) and standard error of mean (SEM) should be determined.
    [Show full text]
  • Pharmacology Part 2: Introduction to Pharmacokinetics
    J of Nuclear Medicine Technology, first published online May 3, 2018 as doi:10.2967/jnmt.117.199638 PHARMACOLOGY PART 2: INTRODUCTION TO PHARMACOKINETICS. Geoffrey M Currie Faculty of Science, Charles Sturt University, Wagga Wagga, Australia. Regis University, Boston, USA. Correspondence: Geoff Currie Faculty of Science Locked Bag 588 Charles Sturt University Wagga Wagga 2678 Australia Telephone: 02 69332822 Facsimile: 02 69332588 Email: [email protected] Foot line: Introduction to Pharmacokinetics 1 Abstract Pharmacology principles provide key understanding that underpins the clinical and research roles of nuclear medicine practitioners. This article is the second in a series of articles that aims to enhance the understanding of pharmacological principles relevant to nuclear medicine. This article will build on the introductory concepts, terminology and principles of pharmacodynamics explored in the first article in the series. Specifically, this article will focus on the basic principles associated with pharmacokinetics. Article 3 will outline pharmacology relevant to pharmaceutical interventions and adjunctive medications employed in general nuclear medicine, the fourth pharmacology relevant to pharmaceutical interventions and adjunctive medications employed in nuclear cardiology, the fifth the pharmacology related to contrast media associated with computed tomography (CT) and magnetic resonance imaging (MRI), and the final article will address drugs in the emergency trolley. 2 Introduction As previously outlined (1), pharmacology is the scientific study of the action and effects of drugs on living systems and the interaction of drugs with living systems (1-7). For general purposes, pharmacology is divided into pharmacodynamics and pharmacokinetics (Figure 1). The principle of pharmacokinetics is captured by philosophy of Paracelsus (medieval alchemist); “only the dose makes a thing not a poison” (1,8,9).
    [Show full text]
  • Technical Expert Group on Drug Efficacy and Response 1–2 June 2017 Room M 605, Headquarters, World Health Organization, Geneva, Switzerland
    Global Malaria Programme Technical Expert Group on Drug Efficacy and Response 1–2 June 2017 Room M 605, Headquarters, World Health Organization, Geneva, Switzerland Minutes of the Technical Expert Group on Drug Efficacy and Response This document was prepared as a pre-read for the meeting of the Malaria Policy Advisory Committee and is not an official document of the World Health Organization. WHO/HTM/GMP/MPAC/201712 Page 2 of 35 Minutes of the Technical Expert Group on Drug Efficacy and Response Contents Acknowledgments ................................................................................................................................... 4 Abbreviations .......................................................................................................................................... 4 Summary and recommendations............................................................................................................ 5 1 Welcome and introduction of guest speakers ................................................................................ 9 2 Declarations of interest................................................................................................................... 9 3 Minutes and action points of TEG 2015 .......................................................................................... 9 4 Session 1. Molecular markers: genotyping and monitoring drug resistance ................................. 9 4.1 Molecular markers of piperaquine resistance .......................................................................
    [Show full text]